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Introduction {#sec005}
============

Reliable detection of latent tuberculosis infection (LTBI) is a priority as this will help direct appropriate use of limited resources for tuberculosis (TB) control. One-third of the world's population have LTBI with 10% of these individuals eventually developing active TB \[[@pone.0188631.ref001]\]. The risk of progression from LTBI to active TB is considerably higher in the presence of predisposing factors such as immune-compromised conditions \[[@pone.0188631.ref002]\]. Treatment costs of TB, particularly multi-drug-resistant infection are high \[[@pone.0188631.ref003]\]. Cases with pulmonary TB disease are the source of ongoing transmission in the community.

Diagnosis of LTBI suffers from the absence of a gold standard test. The tuberculin skin test (TST) remains the most widely used principally due to its low cost. However, it is substantially affected by cross-reactivity with non-tuberculous mycobacterial proteins found in the Bacillus Calmette-Guérin (BCG) vaccine, causing false-positive test results \[[@pone.0188631.ref004]\]. Interferon-gamma release assays (IGRAs), including the commercially available assays QuantiFERON-TB Gold In Tube (QFT-GIT; Qiagen, Hilden, Germany), and the T-SPOT.TB (Oxford Immunotec, Oxfordshire, UK), are used as alternatives to TST in settings where higher test acquisition costs can be supported. IGRAs are thought to be more specific than TST as they measure interferon-gamma released by T-cells after stimulation with *Mycobacterium tuberculosis*-specific antigens absent in BCG and most non-tuberculosis mycobacteria \[[@pone.0188631.ref005]\].

The diagnostic performance of IGRAs for LTBI in clinical practice has been evaluated in a number of studies in immune-competent adults, which largely show that these tests have higher specificity than TST \[[@pone.0188631.ref006],[@pone.0188631.ref007]\]. The data on the reliability of IGRAs for the diagnosis of LTBI in immune-compromised adults and children have not been resolved with certainty. Without a gold standard, the true prevalence of disease and accuracy of diagnostic tests are difficult to measure reliably. Many studies have instead compared the performance of IGRAs against TST by evaluating the agreement between these tests.

Bayesian latent class models can be used to make inferences about disease prevalence and the sensitivity and specificity of diagnostic tests using data on the concordance between tests \[[@pone.0188631.ref008]--[@pone.0188631.ref010]\]. This approach is based on the notion that the observed results of various imperfect diagnostic tests for the same disease are influenced by an underlying unobserved (i.e. latent) variable, the true disease status \[[@pone.0188631.ref008]--[@pone.0188631.ref010]\]. In this study, we used the Bayesian latent class modelling approach to evaluate the diagnostic performance of IGRAs (QFT-GIT and T-SPOT.TB) and TST for the diagnosis of LTBI in various population groups.

Methods {#sec006}
=======

Search strategy and selection criteria {#sec007}
--------------------------------------

A systematic literature search of PubMed, Embase and African Index Medicus databases was conducted on September 11, 2017 to identify original studies that evaluated the concordance between TST and QFT-GIT or T-SPOT.TB for the diagnosis of LTBI in human subjects. The search included the following Medical Subject Headings (MeSH) terms or text key words: (tuberculin\[mesh\]) OR "TST" OR "Mantoux") and ("interferon gamma release assay" OR "interferon gamma assay" OR "QuantiFero\*" OR "IGRA" OR "T-SPO\*" OR "TSPO\*" OR "Elispot" OR CFP10 OR ESAT6) and (tuberculosis\[mesh\]). No restrictions on date, language, or type of studies were applied. The full search strategy is described in [S1 Text](#pone.0188631.s001){ref-type="supplementary-material"}. Secondary searching of the reference lists of relevant articles and reviews was also performed for saturation. Titles and abstracts were screened by three authors (TD, AS, and GS) to remove articles that were not relevant to our study. After this initial screening, full-texts of potentially relevant studies were obtained and reviewed independently by at least two of the authors (TD, DE, AS, and GS). Articles were included in this study if they met the following data criteria: 2x2 agreement tables or sufficient information that allowed the construction of such tables between TST and QFT-GIT or T-SPOT.TB; used a TST cut-off value of 5 mm or 10 mm; included IGRAs that were commercial versions using a mixture of the synthetic peptides ESAT-6 and CFP-10; and that the tests were used for the diagnosis of LTBI. This study was reported in accordance with the PRISMA Statement \[[@pone.0188631.ref011]\]. The review protocol was registered with the International prospective register of systematic reviews (PROSPERO) (CRD42017060705).

Data synthesis and analysis {#sec008}
---------------------------

Data from each eligible study were extracted by two independent reviewers. Discrepancies between the two reviewers were resolved by consensus or by consultation with a third reviewer (DE) if consensus could not be reached. The following variables were extracted: year of publication, country of origin, population group, BCG vaccination rate, TST cut-off value, methods of IGRAs, age range and mean/median where available, proportion of participants on immunosuppressive therapy, and 2x2 test agreement data (TST+/IGRA+, TST+/IGRA-, TST-/IGRA+, TST-/IGRA-). If separate agreement tables were available for different subgroups of patients, these data were included separately \[[@pone.0188631.ref006]\]. Authors were contacted for further information where appropriate. The QUADAS-2 checklist for the quality assessment of diagnostic accuracy studies was used for quality assessment of the included studies \[[@pone.0188631.ref012]\]. A description of the QUADAS-2 items can be found in [S2 Text](#pone.0188631.s002){ref-type="supplementary-material"}.

The primary outcome was the diagnostic performance, i.e. sensitivity, specificity, positive predictive value and negative predictive value, of TST, QFT-GIT and T-SPOT.TB in immune-competent adults aged 15 years or above. For studies to be included in this primary analysis, the prevalence of immune-compromised conditions had to be less than 5% \[[@pone.0188631.ref006]\]. Subgroup analyses investigating the diagnostic performance of TST and QFT-GIT were performed on immune-competent children (≤ 14 years of age) and immune-compromised adults. Subgroup analyses on these population groups were not performed with T-SPOT.TB due to insufficient data. In accordance with international guidelines \[[@pone.0188631.ref013]--[@pone.0188631.ref015]\] and real-life clinical practice, we used a TST cut-off value of 10 mm for immune-competent subjects and 5 mm for immune-compromised individuals. We allowed for factors that could potentially lead to variability of diagnostic test performance between studies including BCG vaccination rate and immune status.

Bayesian latent class model {#sec009}
---------------------------

We developed a Bayesian latent class model to describe the observed 2x2 data to estimate the true prevalence (*π*) of LTBI in the population, and the sensitivity (*S*~1~, *S*~2~) and specificity (*C*~1~, *C*~2~) of TST (test 1, *T*~1~) and IGRA (test 2, *T*~2~). Let *D* be the unknown (latent) true disease status, the prevalence, sensitivity and specificity can be formally expressed as follows: $$\pi = P\left( {D +} \right),S_{1} = P\left( {T_{1} +}\left| D + \right. \right),S_{2} = P\left( {T_{2} +}\left| D + \right. \right),C_{1} = P\left( {T_{1} -}\left| D - \right. \right),\ and\ C_{2} = P\left( {T_{2} -}\left| D - \right. \right).$$ The observed data follow a multinomial distribution where each probability of the four combinations of the results of the two tests can be expressed in terms of *π*, *S*~1~, *S*~2~, *C*~1~ and *C*~2~ as follows: $$\begin{array}{l}
{P\left( {T_{1} + ,\ T_{2} +} \right) = \pi S_{1}S_{2} + \left( {1 - \pi} \right)\left( {1 - C_{1}} \right)\left( {1 - C_{2}} \right);} \\
{P\left( {T_{1} + ,\ T_{2} -} \right) = \pi S_{1}\left( 1 - S_{2} \right) + \left( {1 - \pi} \right)\left( {1 - C_{1}} \right)C_{2};} \\
{P\left( {T_{1} - ,\ T_{2} +} \right) = \pi\left( 1 - S_{1} \right)S_{2} + \left( {1 - \pi} \right)C_{1}\left( {1 - C_{2}} \right);} \\
{P\left( {T_{1} - ,\ T_{2} -} \right) = \pi\left( {1 - S_{1}} \right)\left( {1 - S_{2}} \right) + \left( {1 - \pi} \right)C_{1}C_{2}.} \\
\end{array}$$

In the latent class model in [Eq 2](#pone.0188631.e002){ref-type="disp-formula"}, *π*, *S*~1~, *S*~2~, *C*~1~ and *C*~2~ were the unknown model parameters to be estimated. A Bayesian approach was used to make inferences about these unknown parameters. This approach combines the observed data, i.e. 2x2 table, and prior knowledge about the parameters formally expressed as a prior probability distribution, to obtain a posterior probability distribution of the unknown parameters. We assumed a beta(*α*,*β*) distribution for the priors of the sensitivity and specificity. Beta distribution was chosen because its region of positive density ranges from 0 to 1, matching the range of these parameters \[[@pone.0188631.ref008]\]. It also has the advantage of being flexible, allowing a wide variety of the shapes of the distribution to be determined by selecting different choices of *α* and *β* \[[@pone.0188631.ref008]\]. The *α* and *β* parameters of the beta distributions of the sensitivity and specificity of *T*~1~ and *T*~2~ were determined by equating the midpoint of the range reported in the literature to the mean (*μ*) of the beta distribution, and equating one quarter of the range to the standard deviation (*δ*) of the beta distribution \[[@pone.0188631.ref010]\]. The mean, standard deviation and the parameters of a beta distribution were given by the following equations: $$\begin{array}{l}
{\mu = \frac{\alpha}{\alpha + \beta};} \\
{\delta = \sqrt{\frac{\alpha\beta}{\left( {\alpha + \beta} \right)^{2}\left( \alpha + \beta + 1 \right)}};} \\
{\alpha = - \frac{\mu\left( {\delta^{2} + \mu^{2} - \mu} \right)}{\delta^{2}};} \\
{\beta = \frac{\left( \mu - 1 \right)\left( \delta^{2} + \mu^{2} - \mu \right)}{\delta^{2}}.} \\
\end{array}$$

For TST (*T*~1~), the sensitivity reported in the literature ranged from 57% to 95% \[[@pone.0188631.ref016],[@pone.0188631.ref017]\], while the specificity ranged from 55% to 100% \[[@pone.0188631.ref018],[@pone.0188631.ref019]\]. Using [Eq 3](#pone.0188631.e003){ref-type="disp-formula"}, these corresponded to beta(14.6, 4.6) and beta(9.9, 2.88) for *S*~1~ and *C*~1~, respectively. The sensitivity of IGRAs reported in the literature ranged from 55% to 93% \[[@pone.0188631.ref018],[@pone.0188631.ref020]\], and their specificity ranged from 89% to 100% \[[@pone.0188631.ref021],[@pone.0188631.ref022]\]. These were converted into beta(15.04, 5.28) and beta(64, 3.7) for *S*~2~ and *C*~2~, respectively. A uniform(0, 0.9) was used for the priors of LTBI prevalence (*π*), knowing that the highest prevalence rate reported in the literature was 90% \[[@pone.0188631.ref023]\]. This distribution assigns equal weights to all possible values from 0 to 0.9 to allow LTBI prevalence to vary freely within this range among studies (i.e. populations). A separate estimate of prevalence for each population was performed.

We also estimated the effect of BCG on the specificity of the tests as follows: $$C_{1i} = pE_{BCG} + \left( {1 - p} \right)C_{1};$$ where *C*~1*i*~ is the specificity of a test in the current (*i*^th^) population, *p* is the proportion of individuals in that population who is vaccinated, and *E*~*BCG*~ is the effect of BCG on the specificity of the test in that population.

Positive predictive value (PPV) and negative predictive value (NPV) were also estimated using the following formulae. [S3 Text](#pone.0188631.s003){ref-type="supplementary-material"} describes how these formulae were derived.
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Bayesian inferences with the Gibbs sampler algorithm was used to estimate the model parameters. For each parameter, three Markov chains were constructed, each chain with different initial values. Convergence of the Markov chains was assessed by visual inspection of the density plots of parameter estimates and by examining the Gelman-Rubin statistics \[[@pone.0188631.ref024]\]. A Gelman-Rubin value of less than 1.1 was considered convergence \[[@pone.0188631.ref024]\]. We ran each chain with 70,000 iterations and a burn-in period of 10,000. For each parameter, median estimates and their 95% credible interval (CrI) were reported. The log-odds ratio check (LORC) method was used for assessment of conditional independence between the two test observations \[[@pone.0188631.ref025]\]. Briefly, the LORC investigates how well a model describes a particular dataset by comparing the empirical pairwise log-odds ratios with the pairwise predicted log-odds ratios \[[@pone.0188631.ref025]\]. The difference between the observed and expected log-odds ratios is expressed by a z-score. A z-score within the ±1.96 range indicates that the assumption of conditional independence is valid \[[@pone.0188631.ref025]\]. All analyses were performed in WinBUGS (version 1.4, Imperial College & Medical Research Council, UK). As this study used data from published literature, ethics approval was not required.

Results {#sec010}
=======

A total of 2,195 articles were identified from the initial searches. After assessment of titles and abstracts, 480 articles were assessed as potentially relevant and their full-texts were reviewed. Of these, 157 articles met the a priori inclusion criteria \[[@pone.0188631.ref026]--[@pone.0188631.ref182]\]. These studies comprised 170 agreement tables. The earliest and latest years of publication were 2006 and 2017, respectively. Of the included studies, four were published in languages other than English (one Polish, three Spanish); however, the full-texts of these studies were already translated into English by the journal. [Fig 1](#pone.0188631.g001){ref-type="fig"} outlines how the final sample size was reached.

![Flowchart of study selection.\
TB, tuberculosis; TST, tuberculin skin test.](pone.0188631.g001){#pone.0188631.g001}

The characteristics of the included studies are shown in [Table 1](#pone.0188631.t001){ref-type="table"}. Eighty seven percent (137/157) of the included studies reported rates of BCG vaccination. The majority (132/157, 84%) of the studies were conducted in adults (≥15 years of age). Twenty five percent (39/157) of the studies were conducted in patients selected because of altered immunity due to the presence of HIV/AIDS, solid organ transplantation, stem cell transplantation, immune-mediated inflammatory diseases, end-stage kidney disease or malignancy. QFT-GIT was the most common IGRA, used in 87% (137/157) of the included studies. T-SPOT.TB was used in 15/157 studies; all of which included only immune-competent adults. The remaining studies (5/150) used both methods.

10.1371/journal.pone.0188631.t001

###### Characteristics of the included studies.
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  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                                    Country                        Population                     Age range (years)   BCG rate (%)    2x2 data[\*](#t001fn001){ref-type="table-fn"}
  ------------------------------------------------------------ ------------------------------ ------------------------------ ------------------- --------------- -----------------------------------------------
  **Immune-competent,**\                                                                                                                                         
  **IGRA = QFT-GIT**                                                                                                                                             

  Diel et al. (2006) \[[@pone.0188631.ref026]\]                Germany                        Contacts                       Any age             50.8            25, 39, 6, 239

  Nakaoka et al. (2006) \[[@pone.0188631.ref027]\]             Nigeria                        Contacts                       1--14               90              40, 14, 8, 93

  Tsiouris et al. (2006) \[[@pone.0188631.ref028]\]            South Africa                   Students                       5--15               72.3            51, 29, 10, 94

  Adetifa et al. (2007) \[[@pone.0188631.ref029]\]             Gambia                         Contacts                       ≥15                 43              69, 16, 33, 57

  Arend et al. (2007) \[[@pone.0188631.ref030]\]               Netherlands                    Unvaccinated                   ≥17                 0               74, 186, 7, 518

  Dogra et al. (2007) \[[@pone.0188631.ref031]\]               India                          Contacts                       1--12               82              8, 2, 3, 92

  Franken et al. (2007) \[[@pone.0188631.ref032]\]             Netherlands                    Military personnel             ≥18                 12.6            19, 120, 2, 535

  Silverman et al. (2007) \[[@pone.0188631.ref033]\]           Canada                         Contacts                       ≥18                 100             3, 10, 0, 9

  Chun et al. (2008) \[[@pone.0188631.ref034]\]                Korea                          Contacts                       ≤13                 100             9, 12, 1, 47

  Healthy controls                                             ≤14                            100                            1, 41, 0, 23                        

  Mirtskhulava et al. (2008) \[[@pone.0188631.ref035]\]        Georgia                        HCW                            18--74              92              133, 44, 26, 62

  Petrucci et al. (2008) \[[@pone.0188631.ref036]\]            Nepal                          Contacts                       ≤15                 84.9            65, 9, 5, 58

  Brazil                                                       Contacts                       ≤15                            84.9                33, 2, 12, 63   

  Baker et al. (2009) \[[@pone.0188631.ref037]\]               USA                            Refugees                       1--81               NR              85, 23, 20, 67

  Bianchi et al. (2009) \[[@pone.0188631.ref038]\]             Italy                          Contacts, Immigrants           ≤16                 51.5            33, 21, 27, 253

  Fox et al. (2009) \[[@pone.0188631.ref039]\]                 Israel                         HCW                            ≥18                 34              9, 22, 8, 52

  Herrmann et al. (2009) \[[@pone.0188631.ref040]\]            France                         HCW                            24--53              100             4, 9, 2, 4

  Kik et al. (2009) \[[@pone.0188631.ref041]\]                 Netherlands                    Contacts                       ≥16                 NR              142, 97, 10, 33

  Kim et al. (2009) \[[@pone.0188631.ref042]\]                 Korea                          Immune-competent               19--98              100             17, 8, 7, 53

  Lien et al. (2009) \[[@pone.0188631.ref043]\]                Vietnam                        HCW                            20--58              32              114, 49, 21, 71

  Lighter et al. (2009) \[[@pone.0188631.ref044]\]             USA                            Mixed                          ≤18                 36              27, 88, 4, 85

  Machado et al. (2009) \[[@pone.0188631.ref045]\]             Brazil                         Contacts                       Any age             76              100, 44, 17, 94

  Ringshausen et al. (2009) \[[@pone.0188631.ref046]\]         Germany                        HCW                            20--62              51              7, 22, 6, 108

  Saracino et al. (2009) \[[@pone.0188631.ref047]\]            Italy                          Immigrants                     Any age             NR              49, 23, 58, 149

  Torres Costa et al. (2009) \[[@pone.0188631.ref048]\]        Portugal                       HCW                            ≥16                 100             371, 532, 26, 289

  Tripodi et al. (2009) \[[@pone.0188631.ref049]\]             France                         HCW                            20--60              100             23, 74, 5, 46

  Vinton et al. (2009) \[[@pone.0188631.ref050]\]              Australia                      HCW                            20--66              78              16, 98, 5, 222

  Zhao et al. (2009) \[[@pone.0188631.ref051]\]                USA                            HCW                            ≥18                 NR              10, 10, 0, 20

  Adetifa et al. (2010) \[[@pone.0188631.ref052]\]             Gambia                         Contacts                       0.5--14             59              43, 14, 29, 127

  Costa et al. (2010) \[[@pone.0188631.ref053]\]               Portugal                       HCW                            ≥16                 100             525, 792, 33, 332

  Grare et al. (2010) \[[@pone.0188631.ref054]\]               France                         Contacts                       ≥18                 45.4            5, 10, 0, 22

  Huang et al. (2010) \[[@pone.0188631.ref055]\]               Taiwan                         Contacts                       Any age             89              12, 24, 3, 39

  Jong Lee et al. (2010) \[[@pone.0188631.ref056]\]            Korea                          HCW                            22--53              100             10, 21, 9, 42

  Katsenos et al. (2010) \[[@pone.0188631.ref057]\]            Greece                         Army recruits                  18--35              100             11, 85, 2, 31

  Lee et al. (2010) \[[@pone.0188631.ref058]\]                 Korea                          Contacts                       16--70              67.2            97, 29, 11, 48

  Torres Costa et al. (2010) \[[@pone.0188631.ref059]\]        Portugal                       HCW                            ≥18                 63.7            525, 792, 33, 332

  Thomas et al. (2010) \[[@pone.0188631.ref060]\]              Bangladesh                     Mixed                          11--15.3            79              72, 16, 35, 105

  Tsolia et al. (2010) \[[@pone.0188631.ref061]\]              Greece                         Mixed                          ≥15                 NR              58, 70, 4, 16

  Caglayan et al. (2011) \[[@pone.0188631.ref062]\]            Turkey                         HCW                            Any age             87              33, 32, 1, 12

  Diel et al. (2011) \[[@pone.0188631.ref063]\]                Germany                        Contacts                       1--62               52              138, 104, 60, 652

  Kasambira et al. (2011) \[[@pone.0188631.ref064]\]           South Africa                   Contacts                       ≤16                 95              48, 7, 27, 154

  Kus et al. (2011) \[[@pone.0188631.ref065]\]                 Poland                         Healthy                        ≥18                 100             85, 140, 41, 186

  Legesse et al. (2011) \[[@pone.0188631.ref066]\]             Ethiopia                       General                        18--70              17.4            151, 16, 76, 28

  Moon et al. (2011) \[[@pone.0188631.ref067]\]                Korea                          HCW                            22--67              100             18, 34, 14, 90

  Moyo et al. (2011) \[[@pone.0188631.ref068]\]                South Africa                   Contacts                       ≤3                  100             57, 13, 11, 295

  Pavic et al. (2011) \[[@pone.0188631.ref069]\]               Croatia                        Contacts                       0--5                100             14, 11, 4, 112

  Rafiza et al. (2011) \[[@pone.0188631.ref070]\]              Malaysia                       HCW                            19--56              99.7            11, 45, 2, 37

  Shanaube et al. (2011) \[[@pone.0188631.ref071]\]            Zambia, South Africa           Contacts                       ≥15                 NR              577, 148, 570, 508

  Talebi-Taher et al. (2011) \[[@pone.0188631.ref072]\]        Iran                           HCW                            23--59              100             14, 91, 3, 92

  Torres Costa et al. (2011) \[[@pone.0188631.ref073]\]        Portugal                       HCW                            ≥18                 68.2            850, 1252, 103, 679

  Torres Costa et al. (2011) \[[@pone.0188631.ref074]\]        Portugal                       HCW                            ≥16                 98.6            153, 344, 8, 67

  Weinfurter et al. (2011) \[[@pone.0188631.ref075]\]          USA                            Mixed                          ≥13                 36              167, 155, 64, 1267

  Yassin et al. (2011) \[[@pone.0188631.ref076]\]              Ethiopia                       Contacts                       ≥15                 52              87, 39, 24, 59

  Healthy controls                                             ≥15                            52                             6, 10, 12, 86                       

  Bergot et al. (2012) \[[@pone.0188631.ref077]\]              France                         Contacts                       12--97              20.4            28, 50, 7, 62

  Di Renzi et al. (2012) \[[@pone.0188631.ref078]\]            Italy                          Staff of homeless shelter      25--71              6.5             22, 0, 2, 27

                                                                                              Healthy controls               ≥18                 66              16, 12, 3, 10

  He et al. (2012) \[[@pone.0188631.ref079]\]                  Mongolia                       HCW                            18--72              26              350, 89, 288, 190

  Jeong et al. (2012) \[[@pone.0188631.ref080]\]               Korea                          X-ray healed TB                36--88              42.6            79, 10, 48, 26

  Jo et al. (2012) \[[@pone.0188631.ref081]\]                  Korea                          Contacts                       Any age             78.2            34, 14, 20, 33

  Jung da et al. (2012) \[[@pone.0188631.ref082]\]             Korea                          Medical students               ≥18                 86.3            6, 17, 2, 128

  Larcher et al. (2012) \[[@pone.0188631.ref083]\]             Italy                          HCW                            19--64              38              57, 103, 24, 365

  Onur et al. (2012) \[[@pone.0188631.ref084]\]                Turkey                         Outpatient paediatric clinic   ≤14                 87.6            33, 18, 4, 36

  Pattnaik et al. (2012) \[[@pone.0188631.ref085]\]            India                          Contacts                       ≥15                 40.7            64, 24, 1, 11

  Zwerling et al. (2012) \[[@pone.0188631.ref086]\]            Canada                         HCW                            ≥18                 36.1            7, 15, 17, 348

  Jo et al. (2013) \[[@pone.0188631.ref087]\]                  Korea                          HCW                            ≥20                 81              54, 127, 31, 281

  Serrano-Escobedo et al. (2013) \[[@pone.0188631.ref088]\]    Mexico                         Contacts                       ≥18                 87              31, 11, 20, 61

  Whitaker et al. (2013) \[[@pone.0188631.ref089]\]            Georgia                        HCW                            ≥18                 89              68, 38, 9, 39

  Zwerling et al. (2013) \[[@pone.0188631.ref090]\]            Canada                         HCW                            ≥18                 61.6            3, 10, 10, 234

  Alvarez et al. (2014) \[[@pone.0188631.ref091]\]             Canada                         High risk groups               Any age             73              46, 40, 4, 166

  Charisis et al. (2014) \[[@pone.0188631.ref092]\]            Greece                         HCW                            ≥20                 68              30, 179, 2, 32

  de Souza et al. (2014) \[[@pone.0188631.ref093]\]            Brazil                         HCW                            ≥18                 86.4            114, 138, 58, 322

  Erkens et al. (2014) \[[@pone.0188631.ref094]\]              Netherlands                    Mixed                          Any age             40              870, 1777, 66, 639

  Garazzino et al. (2014) \[[@pone.0188631.ref095]\]           Italy                          General                        ≤2                  NR              0, 10, 9, 463

  Garcell et al. (2014) \[[@pone.0188631.ref096]\]             Qatar                          HCW                            ≥18                 NR              10, 9, 1, 182

  Goodwin et al. (2014) \[[@pone.0188631.ref097]\]             USA                            Army recruits                  17--36              1               1, 13, 5, 2062

  Mathad et al. (2014) \[[@pone.0188631.ref098]\]              India                          Pregnant women                 ≥18                 NR              46, 12, 79, 206

  Ribeiro-Rodrigues et al. (2014) \[[@pone.0188631.ref099]\]   Brazil                         Contacts                       0.5--87             77.3            159, 36, 14, 100

  Sauzullo et al. (2014) \[[@pone.0188631.ref100]\]            Italy                          HCW                            25--60              3.1             34, 29, 0, 126

  Song et al. (2014) \[[@pone.0188631.ref101]\]                Korea                          Contacts                       11--19              61              231, 430, 86, 2219

  Adams et al. (2015) \[[@pone.0188631.ref102]\]               South Africa                   HCW                            ≥18                 92              293, 112, 24, 53

  El-Sokkary et al. (2015) \[[@pone.0188631.ref103]\]          Egypt                          HCW                            ≥18                 92.4            26, 52, 12, 42

  Gao et al. (2015) \[[@pone.0188631.ref104]\]                 China                          Mixed                          ≥5                  50.6            2933, 2945, 1013, 13587

  Goebel et al. (2015) \[[@pone.0188631.ref105]\]              Australia                      Contacts                       Any age             84              160, 194, 18, 91

  He et al. (2015) \[[@pone.0188631.ref106]\]                  Mongolia                       HCW                            19--77              36.4            122, 45, 276, 422

  Howley et al. (2015) \[[@pone.0188631.ref107]\]              Vietnam, Philippines, Mexico   Migrants to USA                2--14               100             111, 553, 31, 1812

  Jones-Lopez et al. (2015) \[[@pone.0188631.ref108]\]         Uganda                         Contacts                       ≥10                 2               182, 19, 15, 36

  Lucet et al. (2015) \[[@pone.0188631.ref109]\]               France                         HCW                            ≥18                 97.4            95, 348, 18, 343

  Ferrarini et al. (2016) \[[@pone.0188631.ref110]\]           Brazil                         Contacts                       ≤15                 98.3            31, 3, 3, 4

  Al Hajoj et al. (2016) \[[@pone.0188631.ref111]\]            Saudi Arabia                   HCW                            ≥18                 90.6            227, 275, 172, 921

  Biraro et al. (2016) \[[@pone.0188631.ref112]\]              Uganda                         Contacts                       0--30               78              62, 7, 92, 76

  Bozkanat et al. (2016) \[[@pone.0188631.ref113]\]            Turkey                         HCW                            ≥18                 94.1            7, 21, 0, 6

  Grare et al. (2010) \[[@pone.0188631.ref114]\]               France                         Children                       NR                  41              5, 7, 0, 32

  Lowenthal et al. (2016) \[[@pone.0188631.ref115]\]           USA                            Immigrants                     2--14               NR              142, 523, 3, 48

  Marco Mourino et al. (2011) \[[@pone.0188631.ref116]\]       Spain                          Prisoners                      19--66              17              27, 13, 10, 99

  Marquez et al. (2016) \[[@pone.0188631.ref117]\]             Uganda                         Children                       0--5                94              10, 114, 10, 343

  Miramontes et al. (2015) \[[@pone.0188631.ref118]\]          USA                            General                        ≥6                  NR              127, 158, 176, 5603

  Mostafavi et al. (2016) \[[@pone.0188631.ref119]\]           Iran                           HCW                            ≥20                 86              13, 26, 29, 176

  Nienhaus et al. (2011) \[[@pone.0188631.ref120]\]            Germany, Portugal, France      HCW                            ≥18                 NR              409, 654, 41, 523

  Oren et al. (2016) \[[@pone.0188631.ref121]\]                USA                            Migrant farmers                ≥48                 74              16, 8, 12, 32

  Pavic et al. (2015) \[[@pone.0188631.ref122]\]               Croatia                        Contacts                       \<5                 98.8            18, 13, 8, 132

  Reechaipichitkul et al. (2015) \[[@pone.0188631.ref123]\]    Thailand                       Contacts                       NR                  86              15, 24, 5, 56

  Rose et al. (2015) \[[@pone.0188631.ref124]\]                Canada                         Contacts                       0--17               42              27, 16, 4, 47

  Salinas et al. (2015) \[[@pone.0188631.ref125]\]             Spain                          Immigrants                     12--18              26.75           140, 103, 2, 34

  Sharma et al. (2017) \[[@pone.0188631.ref126]\]              India                          Contacts                       1--65               76              540, 187, 377, 394

  Yoo et al. (2016) \[[@pone.0188631.ref127]\]                 Korea                          Contacts                       NR                  84              92, 71, 40, 241

  Anibarro et al. (2011) \[[@pone.0188631.ref128]\]            Spain                          Contacts                       ≥18                 36              68, 14, 5, 50

  Diel et al. (2008) \[[@pone.0188631.ref129]\]                Germany                        Contacts                       1--56               46              62, 181, 4, 354

  Ferreira et al. (2015) \[[@pone.0188631.ref130]\]            Brazil                         Contacts                       ≥18                 86.7            19, 5, 9, 27

  Nienhaus et al. (2008) \[[@pone.0188631.ref131]\]            Germany                        HCW                            18--67              37.5            15, 48, 10, 188

  **Immune-competent,**\                                                                                                                                         
  **IGRA = T-SPOT.TB**                                                                                                                                           

  Porsa et al. (2006) \[[@pone.0188631.ref132]\]               USA                            Prisoners                      ≥18                 NR              9, 28, 13, 359

  Arend et al. (2007) \[[@pone.0188631.ref030]\]               Netherlands                    Unvaccinated                   ≥17                 0               103, 151, 39, 466

  Rangaka et al. (2007) \[[@pone.0188631.ref133]\]             South Africa                   Mixed                          Any age             71              40, 21, 5, 8

  Bienek & Chang (2009) \[[@pone.0188631.ref134]\]             USA                            Unvaccinated                   18--41              3               2, 0, 6, 318

  Janssens et al. (2008) \[[@pone.0188631.ref135]\]            Switzerland                    Contacts                       16--83              80.6            78, 65, 37, 100

  Leung et al. (2008) \[[@pone.0188631.ref136]\]               Hong Kong                      Silicosis                      ≥18                 1.5             72, 20, 14, 28

  Soysal et al. (2008) \[[@pone.0188631.ref137]\]              Turkey                         Healthy                        Any age             83              7, 18, 0, 21

  Girardi et al. (2009) \[[@pone.0188631.ref138]\]             Italy                          HCW                            ≥18                 37.4            37, 24, 5, 49

  Hansted et al. (2009) \[[@pone.0188631.ref139]\]             Lithuania                      Contacts                       10--17              100             7, 20, 1, 17

                                                                                              Low risk                       10--17              100             3, 31, 2, 16

  Kik et al. (2009) \[[@pone.0188631.ref041]\]                 Netherlands                    Contacts                       ≥16                 NR              154, 85, 14, 29

  Adetifa et al. (2010) \[[@pone.0188631.ref052]\]             Gambia                         Contacts                       0.5--14             59              43, 14, 27, 129

  Leung et al. (2010) \[[@pone.0188631.ref140]\]               Hong Kong                      Silicosis                      ≥18                 3.5             168, 35, 36, 69

  Borkowska et al. (2011) \[[@pone.0188631.ref141]\]           Poland                         HCW                            27--73              100             7, 4, 0, 6

  Zhao et al. (2011) \[[@pone.0188631.ref142]\]                China                          Students                       17--24              0               11, 26, 16, 103

  Larcher et al. (2012) \[[@pone.0188631.ref083]\]             Italy                          HCW                            19--64              38              24, 51, 35, 282

  Nkurunungi et al. (2012) \[[@pone.0188631.ref143]\]          Uganda                         Healthy                        ≤5                  100             17, 6, 51, 218

  Adams et al. (2015) \[[@pone.0188631.ref102]\]               South Africa                   HCW                            ≥18                 92              249, 126, 20, 55

  Leung et al. (2015) \[[@pone.0188631.ref144]\]               Hong Kong                      Contacts                       5--64               66              254, 228, 89, 478

  Spicer et al. (2015) \[[@pone.0188631.ref145]\]              USA                            Mixed                          0.3--16             72.5            5, 18, 0, 71

                                                                                              Non-TB diseases                25--63              100             0, 3, 1, 26

  **Immune-compromised,**\                                                                                                                                       
  **IGRA = QFT-GIT**                                                                                                                                             

  Mendez-Echevarria et al. (2011) \[[@pone.0188631.ref146]\]   Spain                          IMID                           ≥18                 5.6             4, 3, 5, 37

  Moon et al. (2011) \[[@pone.0188631.ref067]\]                Korea                          Stem cell transplant           35--55              82              9, 24, 31, 146

  Takahashi et al. (2007) \[[@pone.0188631.ref147]\]           USA                            HIV                            22--79              7.4             2, 5, 7, 259

  Aichelburg et al. (2014) \[[@pone.0188631.ref148]\]          Austria                        HIV                            ≥18                 NR              24, 3, 13, 195

  Balcells et al. (2008) \[[@pone.0188631.ref149]\]            Chile                          HIV                            21--71              88              9, 2, 8, 90

  Bourgarit et al. (2015) \[[@pone.0188631.ref150]\]           France                         HIV                            ≥18                 60.6            20, 42, 14, 316

  Casas et al. (2011) \[[@pone.0188631.ref151]\]               Spain                          IMID                           NR                  26              43, 19, 13, 210

  Casas et al. (2011) \[[@pone.0188631.ref152]\]               Spain                          ESRD                           NR                  31.6            34, 10, 9, 42

  Chkhartishvili et al. (2013) \[[@pone.0188631.ref153]\]      Georgia                        HIV                            ≥18                 94              25, 16, 44, 148

  Gogus et al. (2010) \[[@pone.0188631.ref154]\]               Turkey                         IMID                           20--70              100             8, 17, 1, 12

  Hanta et al. (2012) \[[@pone.0188631.ref155]\]               Turkey                         IMID                           ≥18                 92              24, 32, 10, 24

  Hsia et al. (2012) \[[@pone.0188631.ref156]\]                Worldwide                      IMID                           All age             34.2            59, 150, 101, 1931

  James et al. (2014) \[[@pone.0188631.ref157]\]               India                          HIV                            ≥18                 100             10, 16, 4, 18

  Jones et al. (2007) \[[@pone.0188631.ref158]\]               USA                            HIV                            All age             2               5, 8, 6, 172

  Karadag et al. (2010) \[[@pone.0188631.ref159]\]             Turkey                         IMID                           All age             100             19, 34, 2, 39

  Khawcharoenporn et al. (2015) \[[@pone.0188631.ref160]\]     Thailand                       HIV                            17--65              73              8, 16, 12, 114

  Kim et al. (2014) \[[@pone.0188631.ref161]\]                 Korea                          IMID                           All age             70.7            56, 77, 12, 269

  Kim et al. (2013) \[[@pone.0188631.ref162]\]                 Korea                          IMID                           All age             NR              102, 133, 81, 408

  Kim et al. (2015) \[[@pone.0188631.ref163]\]                 Korea                          IMID                           All age             NR              52, 67, 26, 271

  Latorre et al. (2014) \[[@pone.0188631.ref164]\]             Spain                          IMID                           ≥18                 NR              1, 6, 11, 81

  Manuel et al. (2007) \[[@pone.0188631.ref165]\]              Canada                         Liver transplant               ≥18                 82              18, 9, 16, 98

  Matulis et al. (2008) \[[@pone.0188631.ref166]\]             Switzerland                    IMID                           ≥18                 83              10, 34, 5, 60

  Minguez et al. (2012) \[[@pone.0188631.ref167]\]             Spain                          IMID                           ≥18                 5.6             4, 3, 5, 37

  Moon et al. (2013) \[[@pone.0188631.ref168]\]                Korea                          Stem cell transplant           35--55              82              9, 24, 31, 146

  Papay et al. (2011) \[[@pone.0188631.ref169]\]               Austria                        IMID                           NR                  100             6, 20, 9, 157

  Ramos et al. (2013) \[[@pone.0188631.ref170]\]               Spain                          IMID                           16--82              19              13, 30, 2, 107

  Ramos et al. (2012) \[[@pone.0188631.ref171]\]               Spain                          HIV                            15--85              15.8            21, 25, 8, 40

  Sauzullo et al. (2010) \[[@pone.0188631.ref172]\]            Italy                          IMID                           18--80              8.7             27, 26, 5, 11

  Talati et al. (2009) \[[@pone.0188631.ref173]\]              USA                            HIV                            22--79              7.4             2, 5, 7, 259

  Vassilopoulos et al. (2011) \[[@pone.0188631.ref174]\]       Greece                         IMID                           ≥18                 76              17, 41, 15, 82

  Hoffmann et al. (2010) \[[@pone.0188631.ref175]\]            Switzerland                    Haemodialysis                  30--87              18              5, 2, 4, 21

  Mariette et al. (2012) \[[@pone.0188631.ref176]\]            France                         IMID                           All age             65.7            24, 114, 15, 239

  Ponce de Leon et al. (2008) \[[@pone.0188631.ref177]\]       Peru                           IMID                           All age             80.2            21, 6, 24, 50

  Scrivo et al. (2012) \[[@pone.0188631.ref178]\]              Italy                          IMID                           18--80              5.8             2, 11, 3, 82

  Cho et al. (2016) \[[@pone.0188631.ref179]\]                 Korea                          IMID                           NR                  77.9            19, 16, 19, 148

  Kurti et al. (2015) \[[@pone.0188631.ref180]\]               Hungary                        IMID                           18--30              100             7, 28, 5, 126

  Kussen et al. (2016) \[[@pone.0188631.ref181]\]              Brazil                         HIV                            ≥18                 78              9, 4, 12, 115

  Palomar et al. (2011) \[[@pone.0188631.ref182]\]             Spain                          Haemodialysis                  NR                  42.6            7, 9, 3, 26
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* TST+/IGRA+, TST+/IGRA-, TST-/IGRA+, TST-/IGRA-.

ESRD, end stage renal disease; IGRA, interferon gamma release assay; IMID, immune-mediated inflammatory disease; HCW, healthcare worker; NR, not reported; QFT-GIT, QuantiFERON-TB Gold In Tube; TB, tuberculosis.

The results of the quality assessment of the included studies are summarised in [Fig 2](#pone.0188631.g002){ref-type="fig"} and presented for each individual study in [S1 Table](#pone.0188631.s004){ref-type="supplementary-material"}. Many studies did not report all the information that could be used to fully assess the quality of the study. For the "patient selection" domain, most studies (154/157, 98%) were deemed to have low risk of bias ([Fig 2](#pone.0188631.g002){ref-type="fig"}). The remaining 2% were considered to have high risk of bias because these studies used a case-control study design in which the status of LTBI were known prior to the test. For the "diagnostic test domains", risk of bias could not be assessed for the majority of studies because it was unknown whether the results of one test were interpreted without knowledge of the results of the other test ([Fig 2](#pone.0188631.g002){ref-type="fig"}). Nine percent (14/157) of the studies were deemed to have high risk of bias for the "patient flow and timing of tests domain" because there were participants excluded from the analysis without explanation given ([Fig 2](#pone.0188631.g002){ref-type="fig"}). There was unclear risk of bias for this domain for 50% (78/157) of the studies because the interval between the two tests was not reported ([Fig 2](#pone.0188631.g002){ref-type="fig"}).

![Summary of quality assessment results.\
Risk of Bias of each QUADAS-2 domain presented as percentages across the 157 included studies. IGRA; interferon-gamma release assay; TST, tuberculin skin test.](pone.0188631.g002){#pone.0188631.g002}

[Table 2](#pone.0188631.t002){ref-type="table"} shows the estimated sensitivity and specificity of TST, QFT-GIT and T-SPOT.TB in different populations. In immune-competent non-BCG-vaccinated adults, TST has better sensitivity (84% versus 52%) and slightly better specificity (100% versus 97%) than QFT-GIT. BCG vaccination significantly reduces the specificity of TST, from 100% in non-vaccinated subjects to 79% in BCG-vaccinated subjects; whereas the effect of BCG on the specificity of QFT-GIT is modest ([Table 2](#pone.0188631.t002){ref-type="table"}). T-SPOT.TB has comparable specificity (97% for both tests) and better sensitivity (68% versus 52%) than QFT-GIT in immune-competent adults. In immune-compromised adults, QFT-GIT is less sensitive than TST (46% versus 71%) whereas the specificity of both tests is comparable (97% versus 99% in non-BCG-vaccinated adults, 93% for both tests in BCG-vaccinated adults) ([Table 2](#pone.0188631.t002){ref-type="table"}). QFT-GIT and TST have comparable specificity in non-BCG-vaccinated children; however the former is less sensitive than the latter ([Table 2](#pone.0188631.t002){ref-type="table"}). The specificity of QFT-GIT in BCG-vaccinated children is not affected by BCG and is substantially better than that of TST (98% versus 82%) ([Table 2](#pone.0188631.t002){ref-type="table"}).

10.1371/journal.pone.0188631.t002

###### Estimated sensitivity and specificity of TST and IGRAs in different population groups.

![](pone.0188631.t002){#pone.0188631.t002g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter         Diagnostic test     Immune-competent adults[\*](#t002fn001){ref-type="table-fn"}\   Immune-compromised adults[†](#t002fn002){ref-type="table-fn"}\   Immune-competent children[\*](#t002fn001){ref-type="table-fn"}\
                                        median (95% CrI)                                                median (95% CrI)                                                 median (95% CrI)
  ----------------- ------------------- --------------------------------------------------------------- ---------------------------------------------------------------- -----------------------------------------------------------------
  Sensitivity (%)   QFT-GIT             52 (50--53)                                                     46 (43--49)                                                      73 (70--76)

  TST               84 (82--85)         71 (66--75)                                                     82 (79--84)                                                      

  Specificity (%)   QFT-GIT (non-BCG)   97 (96--97)\                                                    97 (96--98)                                                      98 (97--99)

  QFT-GIT (BCG)     93 (92--94)         93 (92--95)                                                     98 (97--99)                                                      

  TST\              100 (99--100)       99 (97--100)                                                    98 (96--99)                                                      
  (non-BCG)                                                                                                                                                              

  TST (BCG)         79 (76--82)         93 (91--96)                                                     82 (81--83)                                                      
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*TST cut-off value = 10 mm

†TST cut-off value = 5 mm

BCG, Bacillus Calmette-Guérin; CrI, credible interval; QFT-GIT, QuantiFERON-TB Gold In Tube; TST, tuberculin skin test.

The mean prevalence of LTBI among the populations where the studies were performed was estimated to be 49% (standard deviation ± 27%). The relationship between prevalence and predictive values is shown in [Fig 3](#pone.0188631.g003){ref-type="fig"}. In a high-prevalence setting (prevalence \> 50%), QFT-GIT has a PPV of at least 88% and a NPV value of at most 69%. The PPV of TST is around 100% in non-BCG-vaccinated and at least 73% in BCG-vaccinated subjects. The NPV of TST was estimated to be 71% and 61% in these populations, respectively.

![Relationship between prevalence and predictive value in immune-competent adults.\
BCG, Bacillus Calmette-Guérin; LTBI, latent tuberculosis infection; NPV, negative predictive value; PPV, positive predictive value; QFT-GIT, QuantiFERON-TB Gold In Tube; TB, tuberculosis; TST, tuberculin skin test.](pone.0188631.g003){#pone.0188631.g003}

Discussion {#sec011}
==========

Accurate identification and subsequent treatment of LTBI is essential to TB control and elimination. The lack of a gold standard for diagnosing LTBI means that the true prevalence of the disease is unknown, and the estimations of the sensitivity and specificity of diagnostic tests are unreliable. This study represents the most comprehensive Bayesian latent class analysis of published data on the performance of TST and IGRAs for the diagnosis of LTBI. We have confirmed that IGRAs have high specificity but that these tests have considerably lower sensitivity than TST in immune-competent populations than had previously been demonstrated \[[@pone.0188631.ref006],[@pone.0188631.ref007],[@pone.0188631.ref183]\]. A meta-analysis by Pai et al.\[*[@pone.0188631.ref007]*\] estimated the pooled sensitivity of QFT and TST to be 70% and 77%, respectively; the specificity of QFT to be 96--99%; and the specificity of TST in non-BCG-vaccinated and BCG-vaccinated populations to be 97% and 59%, respectively. Our estimate of the sensitivity of QFT-GIT is lower than that of Pai et al. \[[@pone.0188631.ref007]\]; however it should be noted that the sensitivity of QFT in Pai et al. \[[@pone.0188631.ref007]\] was estimated in patients with active TB as a surrogate for LTBI. It is plausible that the cellular immune response, which is the measure of QFT, is different between LTBI and active TB disease, being higher with the latter \[[@pone.0188631.ref005]\]. Using a similar latent class modelling approach, Sadatsafavi et al. \[[@pone.0188631.ref006]\] estimated the sensitivity and specificity of QFT in immune-competent adults to be 64.2% and 99.6%, respectively. However, methodological differences make comparison between our results and those of Sadatsafavi et al. \[[@pone.0188631.ref006]\] challenging. Sadatsafavi et al. \[[@pone.0188631.ref006]\], conducted in 2008, is nearly a decade old and only included a very limited number (nineteen) of studies. Since then, a great amount of new studies that compared the diagnostic performance of IGRAs and TST in this setting have been published. Indeed, our search has found that since the study of Sadatsafavi et al. \[[@pone.0188631.ref006]\] was conducted, there have been 132 new studies that are included in our analysis. Sadatsafavi et al. \[[@pone.0188631.ref006]\] combined all versions of QFT in their analysis, assuming no difference between these tests; whereas our study included only the latest QFT-GIT version, which replaced the discontinued older QFT versions. In addition, Sadatsafavi et al. \[[@pone.0188631.ref006]\] only included immune-competent adults; whereas we included not only immune-competent adults but also children and immune-compromised individuals. The study of Sadatsafavi et al. \[[@pone.0188631.ref006]\] is limited to a single database and to studies in English language only. Single database and English-only language restrictions are likely to result in an incomplete coverage of the literature and biased estimates.

Conventional meta-analysis of diagnostic tests simply entails pooling of data to provide pooled estimates of test sensitivity and specificity. Simple pooling of data may cause serious bias due to confounding of disease prevalence in the contributing studies \[[@pone.0188631.ref184]\]. Our latent class modelling approach accounts for the imperfect nature of the tests; and allows us to estimate not only diagnostic parameters (i.e. sensitivity, specificity, predictive values), but also disease prevalence. Unlike conventional meta-analysis, Bayesian latent class modelling incorporates prior information on sensitivity, specificity and disease prevalence, improving the precision of model estimates for these parameters. It also allows for the quantification of the effect of BCG on the performance of the tests, which otherwise is impossible to measure in conventional epidemiological studies and meta-analysis. Before our study, there had been no formal quantification of the effect of BCG on the specificity of IGRAs; even though it is generally thought that such effect, if any, is modest based on the biological mechanism of the tests, rather than on empirical data \[[@pone.0188631.ref185]\]. Our study is the first to quantify the effect of BCG on the specificity of IGRAs. We have found that such effect is minimal, confirming this hypothesis. We have also been able to quantify the decrement in specificity of TST in BCG-vaccinated subjects. To date, studies that investigated the impact of BCG on TST have only reported such effect as relative risk or odds ratio of having positive TST results between subjects with and without BCG \[[@pone.0188631.ref022],[@pone.0188631.ref023],[@pone.0188631.ref167]\]. We have found that BCG negatively affects the performance of TST, reducing the specificity of the test by 21% in the general population. In contrast, QFT-GIT has reasonable sensitivity and superior specificity in BCG-vaccinated subjects, supporting the recommendation that QFT-GIT should be the preferred diagnostic test of LTBI in this setting \[[@pone.0188631.ref177],[@pone.0188631.ref178]\]. Of note, the effect of BCG on the specificity of the tests was inferred in our model based on the rates of BCG vaccination. We did not take into account other factors that are known to potentially affect the diagnostic performance of TST including age at vaccination and time since vaccination because of the lack of data \[[@pone.0188631.ref179]\]. An important assumption underlying Bayesian latent class models is the assumption of conditional independence between the two test observations \[[@pone.0188631.ref025]\]. Using the LORC method, we estimated the z-score to be 0.8, falling within the ± 1.96 range, indicating no violation of the conditional independence assumption. To explore the potential effects that studies deemed to be of high risk of bias may have on the results, we performed an analysis in which these studies were excluded. We found that our results were robust to the inclusion (or exclusion) of these studies ([S2 Table](#pone.0188631.s005){ref-type="supplementary-material"}).

Immune-compromised patients have an increased risk of LTBI reactivation \[[@pone.0188631.ref005]\]. Screening for LTBI is therefore required prior to commencement of immunosuppressive therapies \[[@pone.0188631.ref005]\]. To date, data on the performance of diagnostic tests for LTBI in immune-compromised subjects are limited and the few published studies evaluating the performance of TST and QFT-GIT show conflicting results \[[@pone.0188631.ref005],[@pone.0188631.ref186]\]. We have found that both tests are specific but have suboptimal sensitivity in immune-compromised patients. We believe that more data on the performance of TST and QFT-GIT in this population group are required.

The limitations of our study must be considered. Our results are derived from studies where the estimates of LTBI prevalence vary widely. This is due to the heterogeneity in study settings, populations and methodology of the included studies. Bayesian analysis requires prior information on model parameters. One criticism of Bayesian latent class models is that they may be sensitive to the choice of prior information. This may particularly be the case when there are limited observed data. When the number of observed data are large, as in our study, these begin to dominate any prior information. We believe that we have used the most informative priors obtained from the literature. Furthermore, we performed sensitivity analysis and found that our results are not sensitive to choice of prior ([S3 Table](#pone.0188631.s006){ref-type="supplementary-material"}).

In conclusion, our study represents the most comprehensive Bayesian latent class analysis of the diagnostic accuracy of TST and IGRAs derived from all published agreement data. Our results challenge the current beliefs about the performance of LTBI screening tests and provide important information to guide choice of tests for LTBI screening that will enhance the millennium goals for elimination of TB. Our findings show that IGRAs may be inferior to TST for diagnosing LBTI in non-BCG-vaccinated populations. For BCG-vaccinated individuals, IGRAs appear to be a more favourable choice. IGRAs will therefore allow physicians and TB controllers to better understand the background prevalence of LTBI for targeted preventive therapy in settings where BCG vaccination is widely administered. QFT-GIT and TST have suboptimal sensitivity in immune-compromised patients and results should be interpreted with caution. A combination of both tests could potentially overcome the problems of false-positives in this setting. Considerations regarding cost-effectiveness, logistics, availability for clinicians and patient acceptability should be taken into account to decide which test to use for the diagnosis of LTBI.
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